The global in-vitro fertilization market size is expected to reach USD 5.06 billion by 2025 from USD 2.37 billion in 2020, growing at a CAGR of 16.4% during the forecast period.
The elevation in infertility cases and the evolution of the latest technologies, such as lens less sperm imaging, are estimated to drive the IVF market in the coming years. According to the American Society for Reproductive Medicine (ASRM), the inability to have a child affects approximately 7.1 million women in the United States or about 12.1% of the reproductive population. Additionally, 27% of couples have more than one factor that leads to infertility.
To increase the success rate of in vitro fertilization, researchers have introduced techniques used before the IVF procedure. Currently, advanced techniques are used, such as assisted hatching, verification, egg/sperm freezing, percutaneous aspiration of epidymal sperm and testicular sperm extraction (PESA and TESE), mini-IVF, triparental IVF, and genetic diagnosis.
Obesity is considered to be one of the essential factors of infertility in the population. The fat that gets deposited in a woman's abdomen prevents follicular stimulation, thus producing male hormones. Meanwhile, in men, fat deposits lower testosterone levels, leading to a decrease in sperm production. With the elevation in the global obesity rate due to lifestyle changes, the IVF market is estimated to thrive. Factors such as the increasing prevalence of infertility due to lifestyle changes, constant efforts by industry taxpayers, and government initiatives to offer better reimbursement policies are some of the significant drivers of IVF's market growth.
Furthermore, the expansion of fertility procedures to treat male infertility, such as ICSI, will positively influence the growth of the market. The wide availability of genomic testing to prevent the transfer of genetic diseases during IVF will drive the market growth in the years to come. The growing number of IVF has prompted insurers to cover these procedures, leading to competitive prices, thus lowering treatment costs. These factors will promote the growth of the in vitro fertilization (IVF) market globally.
The elevated risks associated with IVF and ICSI treatment will later hinder the growth of the industry during the forecast period. For instance, according to data published by the Reproductive Science Center, a unique condition called imprint disorders linked with IVF procedures anticipated that the risk of such diseases with IVF treatment was around 2 to 5 for all. Sixteen thousand five hundred births using the IVF technique, while the risk in general cases was 2 in 16,500 normal births. Hence, the potential dangers and congenital disabilities associated with IVF treatment and high-priced IVF treatment are estimated to restrain the market growth during the forecast period.
Impact of COVID-19 on the global IVF market
Numerous ongoing IVF pregnancies have struggled because of the disturbance caused by the COVID-19 pandemic. As every moment is essential in this procedure, many expectant parents, or people planning to begin parenthood through in vitro fertilization (IVF), experience an emotional roller coaster ride due to this current uncertainty. Despite the fact that some clinics have started to operate and there is hope that the situation will improve, the Indian IVF industry, a precursor to treatment, could see reverberations of COVID-19 long after the disappearance of the drug virus. As the pandemic has hit the economy terribly, and liquid assets' availability has been drastically reduced, industry experts believe people's ability to pay will become a significant challenge for the industry.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Reagents & Media, Instruments, Technology, End-Users and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global in-vitro fertilization market has been segmented and sub-segmented based on the reagents & media, instruments, technology, end-users, and region.
In-vitro Fertilization Market - By Reagents and Media:
Based on reagents and media, the cryopreservation media segment accounted for the largest share of the global in-vitro fertilization market by reagents & media in 2018.
In-vitro Fertilization Market -By Instruments:
Based on instruments, the imaging systems segment commanded the largest share of the global in-vitro fertilization market by instruments in 2018. The sperm separation systems segment is expected to grow at the highest CAGR during the forecast period.
In-vitro Fertilization Market - By Technology:
The intracytoplasmic sperm injection segment accounted for the largest share of the global in-vitro fertilization market by technology in 2018.
In-vitro Fertilization Market - By End Users:
Of these, the fertility & surgical centers segment commanded the largest share of the global in-vitro fertilization market by end-users in 2018.
In-vitro Fertilization Market - By Region:
Europe commanded the highest share of 37.0% of the global in-vitro fertilization market in 2019, whereas Asia-Pacific is estimated to grow at the highest CAGR of 18.40% during the forecast period. Asia Pacific accounted for the largest share of the number of IVF cycles performed in 2020 due to the large target population, low cost of treatment compared to developed regions and the availability of advanced technologies. Japan, China, and India have been the main contributors to the region.
The European market generated revenues of USD 8.21 billion in 2020. The rise in the region is credited to the elevating prevalence of infertility. The growing success rate of IVF treatment countries such as Spain and Denmark will further contribute to market evolution in Europe. According to data published by the European Society for Human Reproduction and Embryology (ESHRE), it is reported that the pregnancy rate per treatment in Europe in 2019 was around 33.2%, an elevation of 1.5% per treatment compared to the year above due to the high success rate of IVF and ICSI procedures. In December 2018, the Ontario government announced a $ 55 million fertility program to cover IVF treatment for 6,000 people. Besides, the Singapore government is providing around 78% co-funding for various antiretroviral therapy procedures, such as in vitro fertilization (IVF), intrafallopian gamete transfer (GIFT), and intracytoplasmic sperm injection (ICSI). In January 2015, the Centers for Disease Control and Prevention (CDC) reported that ICSI use had increased from 37.2% in 1998 to about 77.4% in 2015.
Key industry participants in the Global In-Vitro Fertilization Market profiled in the report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).
RECENT MARKET DEVELOPMENTS:
In August 2018, Thomson Medical announced the development of IVF services in China, in cooperation with assisted reproduction specialist IVI-RMA.
February 2018: In-vitro fertilization-focused machine learning company Univfy raised USD 6 million in Series funding. Univfy developed machine learning technology, which aims to reduce the financial burden on those affected by infertility.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Reagents and Media
5.2.1 Introduction
5.2.2 Embryo Culture Media
5.2.3 Cryopreservation Media
5.2.4 Sperm Processing Media
5.2.5 Ovum Processing Media
5.3 Instruments
5.3.1 Introduction
5.3.2 Imaging Systems
5.3.3 Sperm Separation Systems
5.3.4 Ovum Aspiration Pumps
5.3.5 Incubators
5.3.6 Micromanipulator Systems
5.3.7 Cryosystems
5.3.8 Other Instruments (Gas Analyzers, Laser Systems, Accessories)
5.4 Technology
5.3.1 Introduction
5.3.2 Intra-Cytoplasmic Sperm Injection (ICSI)
5.3.3 Pre-Implantation Genetic Diagnosis (PGD)
5.3.4 Frozen Embryo Transfer/Replacement (FET/FER)
5.3.5 Other Technologies
5.5 End Users
5.4.1 Introduction
5.4.2 Fertility and Surgical Centers
5.4.3 Hospitals and Research Laboratories
5.4.4 Cryobanks
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 CooperSurgical, Inc. (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Cook Medical, Inc. (U.S.)
8.3 Irvine Scientific (U.S.)
8.4 Vitrolife AB (Sweden)
8.5 Thermo Fisher Scientific, Inc. (U.S.)
8.6 EMD Serono, Inc. (U.S.)
8.7 Genea Limited (Australia)
8.8 ESCO Micro Pte. Limited (Singapore)
8.9 IVFtech ApS (Denmark)
8.10 The Baker Company, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Feb 2020
Feb 2020
Feb 2020
Feb 2020
